Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending September 30, 2005. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the Company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a regulatory notification of share transactions and does not contain financial performance data.
Material Changes
On September 29, 2005, Abacus (GSK) Trustees Limited, acting as trustee for the GlaxoSmithKline Employee Trust ("the GSK Trust"), transferred 33,522 Ordinary Shares to participants in the SmithKline Beecham Employee Share Option Plan 1991. The Company was advised of these transactions on September 30, 2005.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It notes that the GSK Trust is a discretionary trust where all employees or former employees are potential beneficiaries. Three directors (Dr J-P Garnier, Dr T Yamada, and Mr J S Heslop) hold interests in the shares held by the GSK Trust in the same capacity as other employees. The transaction was notified in accordance with Disclosure Rule 3.1.4R(1)(b).
Key Facts for Investor Verification
- 33,522 Ordinary Shares were transferred from the GSK Trust to employee plan participants on September 29, 2005.
- Three directors have an interest in the GSK Trust shares as potential beneficiaries alongside other employees.
- This filing does not contain quarterly or annual financial results; investors should refer to Form 20-F for financial data.